Cipla

    CIPLA
    Pharma
    ₹1366.00
    price as of 11/9/2026, 5:27:56 pm

    Market cap ₹1.10 L Cr

    P/E
    32.72
    Day range
    ₹1,347.70 – ₹1,373.00
    52-week range
    ₹1,165.70 – ₹1,673.00
    Volume
    16.81 L
    Open
    ₹1,373.00
    Prev close
    ₹1,373.30
    Promoters pledged 2.9% of their shares
    52-week range, adjusted for splits and bonuses
    ₹1,165.7₹1,673
    2 Apr 202623 Oct 2025
    Index membership & F&O
    NIFTY 50NIFTY 100NIFTY 200NIFTY 500NIFTY HEALTHCARENIFTY PHARMAF&O lot 425

    Price history

    6M change +2.75%RSI (14) 34.0 NeutralSMA 20 · 50 overlaid

    Price & delivery on the exchange

    NSE bhavcopy to 11 Sept 2026 · delivery 62.1% today vs 54.9% average · BSE close ₹1,365

    1 Apr23 Apr15 May5 Jun24 Jun15 Jul3 Aug21 Aug11 Sept₹1,190₹1,275₹1,360₹1,445₹1,5300%25%50%75%100%
    • Delivery
    • NSE close
    • BSE close

    High delivery with a rising price suggests buyers holding rather than trading the move.

    Futures & options

    NSE F&O close, 11 Sept 2026 · options expiring 29 Sept 2026

    Long unwinding
    Near-month future
    ₹1,364.8
    Change
    -0.42%
    Basis over spot
    −₹1.19
    Futures OI (shares)
    1.03 Cr
    OI change
    -2.97%
    Put-call ratio
    0.58
    Max pain
    ₹1,400
    Resistance (call OI)
    ₹1,480
    Support (put OI)
    ₹1,300
    Lot size
    425

    Open interest by strike

    Calls open above (resistance) and puts below (support), in shares

    118012401270130013301360139014201450148015101540158002.5 L5.0 L7.5 L10.0 Lspot
    • Call OI
    • Put OI

    Futures open interest and price

    Near-month future, day by day since collection began

    The daily history builds from each close.

    Key metrics

    P/E (TTM)
    35.1
    EPS (TTM)
    ₹41.70
    Price / Book
    3.20
    ROE (FY26)
    11.8%
    ROCE (latest year)
    15%
    Dividend yield
    0.95%
    Net margin (TTM)
    11.9%
    Current ratio
    3.44
    Debt / Equity
    0.01
    Revenue growth (5y)
    8.0%
    EPS growth (5y)
    10.0%

    Moving averages (NSE)

    Simple moving averages of the NSE price, and where the last price sits against each
    5-day10-day20-day50-day100-day300-day
    ₹1,399.9Price below₹1,407.69Price below₹1,425.22Price below₹1,437.81Price below₹1,399.88Price below₹1,394.65Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +7.4%
    Profit 3Y CAGR
    +10.9%
    Revenue YoY (Jun 2026)
    +2.3%
    Profit YoY (Jun 2026)
    -39.2%
    Operating margin
    17.0%
    Net margin
    11.0%

    Revenue, profit & margin - quarterly

    Bars in ₹ crore (a loss shows red); line is operating margin

    Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Jun 20260 Cr2.0K Cr4.0K Cr6.0K Cr8.0K Cr0%7%14%21%28%
    • Revenue
    • Net profit
    • Operating margin

    Who owns the company

    Shareholding as of Jun 2026

    • DII
    • Promoter
    • FII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-6.0K Cr-3.0K Cr0 Cr3.0K Cr6.0K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%5%10%15%20%15%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260 Cr9.0K Cr18.0K Cr27.0K Cr36.0K Cr0.0x0.1x0.2x0.3x0.3x
    • Equity
    • Debt
    • Debt / equity

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales6,6786,6046,1636,6947,0517,0736,7306,9577,5897,0746,5417,119
    Expenses4,9444,8564,8474,9785,1655,0845,1925,1795,6955,8195,5865,927
    Operating Profit1,7341,7481,3161,7161,8861,9891,5381,7781,8951,2559551,192
    OPM %26%26%21%26%27%28%23%26%25%18%15%17%
    Other Income176-10249160191222289259269-70148211
    Interest263018181515141413141317
    Depreciation290233288247272280309253297278383304
    Profit before tax1,5941,4741,2591,6111,7891,9161,5041,7701,8548937071,082
    Tax %28%28%26%27%27%17%19%27%27%24%22%27%
    Net Profit1,1551,0689321,1751,3051,5751,2141,2921,353674543786
    EPS in Rs₹14.01₹13.08₹11.63₹14.58₹16.13₹19.45₹15.13₹16.06₹16.73₹8.37₹6.87₹9.77

    From company filings, updated 11 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

    Strengths, risks & growth

    Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs [1]

    Strengths

    • Company is almost debt free.
    • Company has been maintaining a healthy dividend payout of 25.7%

    Risks

    • The company has delivered a poor sales growth of 8.01% over past five years.
    • Promoter holding has decreased over last 3 years: -4.24%

    Compounded Sales Growth

    10 Years
    +7%
    5 Years
    +8%
    3 Years
    +7%
    TTM
    +2%

    Compounded Profit Growth

    10 Years
    +11%
    5 Years
    +10%
    3 Years
    +10%
    TTM
    -34%

    Stock Price CAGR

    10 Years
    +9%
    5 Years
    +8%
    3 Years
    +3%
    1 Year
    -12%

    Return on Equity

    10 Years
    +13%
    5 Years
    +14%
    3 Years
    +15%
    Last Year
    +12%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderSept 2025Dec 2025Mar 2026Jun 2026Change
    Promoter29.22%29.22%29.22%29.22%0.00 pp
    FII24.54%23.93%22.55%20.20%-2.35 pp
    DII29.98%30.45%31.71%34.35%+2.64 pp
    Government0.27%0.27%0.27%0.28%+0.01 pp
    Public15.99%16.12%16.26%15.93%-0.33 pp

    Filed with NSE for Jun 2026: promoters 29.21%, public 70.79% · XBRL filing

    Analysts & fund holdings

    63%
    63% recommend buy
    35 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E32.7 vs 46.4
    Sector P/B5.84
    Beta0.66

    Who holds the shares, quarter by quarter

    Mutual funds 20.50% (+1.90 pp)
    Mar 25
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    • Promoters29.1%
    • Foreign institutions20.1%
    • Mutual funds20.5%
    • Insurance11.7%
    • Other domestic institutions2.3%
    • Retail6.8%
    • Others9.4%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Flexi Cap Fund2.42%2.47%-0.33 pp
    Parag Parikh Flexi Cap Fund1.75%1.37%-0.10 pp
    ICICI Pru Value Fund0.68%1.30%-0.05 pp
    SBI ELSS Tax Saver Fund0.58%2.11%-0.08 pp
    HDFC Focused Fund0.58%2.37%-1.37 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Corporate actions

    • dividend
      ₹13.00

      Dividend - Rs 13 Per Share

      5 Jun 2026
      ex-date
    • dividend
      ₹13.00

      Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per Share

      27 Jun 2025
      ex-date
    • dividend
      ₹13.00

      Dividend - Rs 13 Per Share

      2 Aug 2024
      ex-date
    • dividend
      ₹8.50

      Dividend - Rs 8.50 Per Share

      21 Jul 2023
      ex-date
    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      8 Aug 2022
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Dividend - Rs 5 Per Share

      9 Aug 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      11 Aug 2020
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3 Per Share Special Dividend - Re 1 Per Share

      19 Mar 2020
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      31 Jul 2019
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend- Rs 3 Per Share

      13 Aug 2018
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2/- Per Share

      26 Jul 2017
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend Rs 2/- Per Share

      12 Sept 2016
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2/- Per Share

      11 Aug 2015
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend Rs 2/- Per Equity Share

      6 Aug 2014
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend Rs 2/- Per Equity Share

      6 Aug 2013
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting And Dividend - Rs.2/- Per Share

      1 Aug 2012
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting And Dividend Rs.2/- Per Share

      9 Aug 2011
      ex-date
    • dividend
      Not available — not reported in this filing

      Special Interim Dividend Re.0.80 Per Share

      3 Sept 2010
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting And Dividend Rs.2/- Per Share

      23 Jul 2010
      ex-date
    • other
      Not available — not reported in this filing

      Agm/Div-Rs.2/- Per Share

      10 Aug 2009
      ex-date

    Insider trades

    Last 12 months, market trades
    No market trades
    1 buys · ₹0
    1 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Renu Jain jointly with Dinesh Jain
    Immediate relative · Gift
    		Buy15,419₹01 Oct 2025
    Anusha Jain jointly with Dinesh Jain
    Immediate relative · Gift
    		Sell15,419₹01 Oct 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Please find enclosed press release titled 'Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US'

    Company Update
    Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August, 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company

    Please find enclosed disclosure

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Please find attached newspaper publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Please find enclosed press release titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)"

    Company Update
    Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA

    Please find enclosed disclosure.

    Company Update
    Announcement under Regulation 30 (LODR)-Restructuring

    Please find enclosed disclosure.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / ....

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    In terms of regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Admisnistrative Committee of the Company on 26th August, 2026 has allotted 5,281 fully ....

    Company Update
    USFDA Inspection At Company'S Manufacturing Facility In Pithampur, India

    Please find enclosed disclosure

    Company Update
    Announcement under Regulation 30 (LODR)-Scheme of Arrangement

    Cipla has informed the exchange about receipt of order from Hon'ble NCLT, Mumbai Bench

    Company Update
    Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Please find attached disclosure on ESG Ratings.

    Company Update
    Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA

    Please find enclosed intimation.

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015, we hereby notify that the Operations and Administrative Committee ....

    Filed with BSE (scrip 500087); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Regulatory orders

    • Order

      Summary Settlement Order in respect of Dr. Ranjana Pathak in the matter of Cipla Limited.

      23 Sept 2019
      Read on SEBI

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 29 Jan 2025 (unaudited). View the source filing. Figures are as filed and are not investment advice.